<p>Novo Nordisk has completed its acquisition of Akero Therapeutics, Inc. The deal, originally announced in October 2025, involved Novo Nordisk purchasing all outstanding shares of Akero for $54 per share in cash, amounting to a total value of $4.7 billion. In addition, holders of Akero shares will receive a non-transferable Contingent Value Right (CVR) that entitles them to an additional $6 per share in cash if Akero’s lead candidate EFX is granted US regulatory approval for the treatment of compensated cirrhosis due to MASH. Following the completion of the transaction, Akero has become a wholly owned subsidiary of Novo Nordisk, and Akero’s common stock will no longer be publicly traded. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001143918-en) on December 09, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

AKRO

<p>Novo Nordisk has completed its acquisition of Akero Therapeutics for $4.7 billion, with Akero becoming a wholly owned subsidiary. Akero shareholders will receive $54 per share and a Contingent Value Right for an additional $6 per share if regulatory approval is granted for Akero's lead candidate EFX. Akero's stock will no longer be publicly traded.</p>

Novo Nordisk Completes Acquisition of Akero Therapeutics